Philadelphia—The multitarget stool DNA test was approved in 2014 for patients with an average risk for colorectal cancer, but new data support expanding its applications to include surveillance of high-risk patients between colonoscopies.
The analyses were based on a large series of cases collected by investigators at Mayo Clinic with the test, MT-sDNA (Cologuard, Exact Sciences). The test shows promise for interval screening between colonoscopies because it has a similar positive